R
Robert J. Fontana
Researcher at University of Michigan
Publications - 396
Citations - 35569
Robert J. Fontana is an academic researcher from University of Michigan. The author has contributed to research in topics: Liver transplantation & Hepatitis C. The author has an hindex of 82, co-authored 355 publications receiving 31311 citations. Previous affiliations of Robert J. Fontana include Harvard University & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Clinical yield of diagnostic endoscopic retrograde cholangiopancreatography in orthotopic liver transplant recipients with suspected biliary complications
B. Joseph Elmunzer,Anthony T. DeBenedet,Michael L. Volk,Christopher J. Sonnenday,Akbar K. Waljee,Robert J. Fontana,Aarti B. Oza,Amit G. Singal,Michael J. Englesbe,James M. Scheiman +9 more
TL;DR: Although T‐ERCP is more likely to reveal a pathological process requiring an intervention, D‐ER CP appears to be an acceptable clinical strategy for OLT recipients because of the high likelihood of a high‐yield study and the low rate of serious complications.
Journal ArticleDOI
A fatal case of bupropion (Zyban) hepatotoxicity with autoimmune features: Case report
TL;DR: This report represents the first fatal report of buPropion related hepatotoxicity and the second case of bupropion related liver injury demonstrating autoimmune features, and is important for physicians to consider this medication as an etiologic agent in patients with otherwise unexplained hepatocellular jaundice.
Journal ArticleDOI
Risk of Liver Injury Associated with Green Tea Extract in SLIMQUICK(®) Weight Loss Products: Results from the DILIN Prospective Study
Elizabeth Zheng,Simona Rossi,Robert J. Fontana,Raj Vuppalanchi,Jay H. Hoofnagle,Ikhlas A. Khan,Victor J. Navarro +6 more
TL;DR: SLIMQUICK® products can lead to severe acute hepatocellular liver injury, which may result in transplantation, and this ingredient should be studied further as a possible cause for liver injury.
Journal ArticleDOI
Curricular guidelines for training in transplant hepatology.
Hugo R. Rosen,Robert J. Fontana,Robert S. Brown,Russell H. Wiesner,Thomas D. Schiano,Nathan M. Bass,Joseph R. Bloomer,Lee Kaplan +7 more
Journal ArticleDOI
The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity
TL;DR: It is concluded that the CBT will not be clinically useful in determining the subset of patients most susceptible to tacrine hepatotoxicity, and first evidence supporting a critical role for CYP1A2 activity in the disposition of the drug in vivo is observed.